TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01370642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to vaniprevir
Description: Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Peg-IFN
Description: Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peg-IFN
Description: Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Study: NCT01984060

Intervention type: OTHER
Group type: OTHER
Intervention: HOME-EX
Description: Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.~Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise
Study: NCT03656575

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: synovial fluid biomarker concentrations
Description: Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: synovial fluid biomarker concentrations
Description: Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
Study: NCT00144300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Requip
Description: Standard marketed product dispensed according to manufacturer's guidelines
Study: NCT02007837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined aspirin and multinutrient supplement
Description: Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily text reminder text messages

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Daily text reminder text messages
Study: NCT03656575

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: synovial fluid biomarker concentrations
Description: Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year
Study: NCT03518203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Eculizumab will be administered as intravenous infusion (IV) over 60 minutes. The dosage form will be 300 mg single-use vials each containing 30 mL of 10 mg/mL sterile, preservative-free solution.
Study: NCT04333654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine SAR321068
Description: Pharmaceutical form:Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT01666080

Intervention type: DRUG
Group type: OTHER
Intervention: Busulfan
Description: 0.4 mg/kg (0.5 mg/kg if \<4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: 40 mg/m\^2 intravenously (IV) over 1 hour on days -6 through -2.

Intervention type: RADIATION
Group type: OTHER
Intervention: Total body irradiation
Description: 200 cGy on Day -1

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem cell transplant
Description: stem cell infusion on day 0

Intervention type: DRUG
Group type: OTHER
Intervention: Keppra
Description: Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
Study: NCT01636544

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contralateral healthy tissue biopsy
Description: At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
Study: NCT03206385

Intervention type: RADIATION
Intervention: Radiation treatment
Description: 50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
Study: NCT01004107

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse Injectable Dermal Filler
Description: Calcium hydroxylapatite particles suspended in an aqueous-based gel carrier
Study: NCT02426086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat 4.7 mg/kg
Description: Participants received imetelstat 4.7 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle. Study drug was administered intravenously until disease progression, unacceptable toxicity, or study end.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imetelstat 9.4 mg/kg
Description: Participants received imetelstat 9.4 mg/kg of body weight as intravenous infusion on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or study end.
Study: NCT02696746

Intervention type: OTHER
Intervention: Observation
Description: No intervention
Study: NCT03478683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide/formoterol
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol
Description: Subjects will be administered two inhalations of budesonide/formoterol via MDI twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.
Study: NCT03206385

Intervention type: RADIATION
Intervention: CK Boost Pelvis
Description: Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
Study: NCT00699166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333
Description: 25 mg and 100 mg oral doses, each taken twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNK333
Description: 25 mg and 100 mg oral doses, each taken twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DNK333
Description: 25 mg and 100 mg oral doses, each taken twice daily
Study: NCT01983904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation with short & long pulse width
Description: surgical implantation for bilateral electrodes and stimulation using short and long pulse width

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deep brain stimulation with short & long pulse width
Description: surgical implantation for bilateral electrodes and stimulation using short and long pulse width
Study: NCT03478683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Subjects will be provided short-acting albuterol/salbutamol as-rescue medication to be used on an as-needed basis throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg via ELLIPTA once daily in the morning
Study: NCT02173366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Change Club Intervention
Study: NCT03478683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match budesonide/formoterol
Description: Subjects will be administered two inhalations of matching placebo twice daily via MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium
Description: Subjects will receive tiotropium (18 mcg) once daily in the morning via HandiHaler device
Study: NCT01829503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine and cytarabine
Study: NCT03478683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to match FF/UMEC/VI
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Study: NCT01829503

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
Study: NCT03492112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCV RNA Point of Care
Description: Participants attending needle syringe programmes in Australia will be screened for hepatitis C using the finger-stick whole blood GeneXpert HCV RNA cartridge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/velpatasvir
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir
Description: Participants with a detectable HCV RNA will be offered treatment with either glecaprevir/pibrentasvir or sofosbuvir/velpatasvir.
Study: NCT01392196

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Renal Denervation
Description: Renal Denervation using the Symplicity Catheter in Heart Failure Population
Study: NCT02507999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flotrac
Description: Flotrac guided intervention
Study: NCT02325895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried Plum
Description: Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dried Plum
Description: Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
Study: NCT02852746

Intervention type: BEHAVIORAL
Intervention: Performance measures of the upper extremity
Description: Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.

Intervention type: BEHAVIORAL
Intervention: Performance measures of the upper extremity
Description: Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
Study: NCT01529151

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular Rehabilitation Therapy (VRT)
Description: Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
Study: NCT03934307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-AGT01
Description: ALN-AGT01 will be administered by subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-AGT01-Matching Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-AGT01-Matching Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALN-AGT01-Matching Placebo
Description: Normal saline (0.9% NaCl) matching volume of ALN-AGT01 doses will be administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: Irbesartan will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan
Description: Irbesartan will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan-Matching Placebo
Description: Irbesartan-matching placebo will be administered orally.
Study: NCT03413917

Intervention type: OTHER
Intervention: Analysis of genomic markers in uterine atony
Description: No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.

Intervention type: OTHER
Intervention: Analysis of genomic markers in uterine atony
Description: No intervention will be performed. We will be analyzing tissue and blood samples only to identify potential association of genomic markers with uterine atony.
Study: NCT03693508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya®
Description: Patents treated with elvitegravir (EVG) 150mg / cobicistat (COBI) 150mg / emtricitabine (FTC) 200mg / tenofovir (TAF) 10mg once a day as the first line treatment.
Study: NCT03374904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Feedback
Description: first, a play interaction between the child and caregiver is recorded (5 to 10 minutes), then the therapist and caregivers watch together a selected part of the video (1 to 2 minutes) and provide feedback with a six step protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Play therapy will be administered once a week plus inpatient treatment as usual for 4 weeks
Study: NCT00676689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SAPIEN Transcatheter Valve Implantation
Description: Device Implantation
Study: NCT03358706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab IV Infusion
Description: Participants will receive a single IV infusion dose of ustekinumab (dosage to be decided based on body weight) on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab SC Injection
Description: Participants will receive a Ustekinumab 90 mg SC maintenance dose on Day 64. A second optional maintenance dose may be administered on Day 120 based on participants clinical response assessed by investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Description: Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Description: Participants will receive 2 milligram per milliliter (mg/ml) syrup of midazolam as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Description: Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin 10 mg
Description: Participants will receive 10 mg tablet of warfarin as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K 10 mg
Description: Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K 10 mg
Description: Participants will receive 10 mg tablet of vitamin K as a component of the Cytochrome P 450 probe cocktail orally.
Study: NCT02164162

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat (Hocoma, Zurich, Switzerland)
Description: Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical treatment
Description: Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
Study: NCT03251404

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injury prevention exercise programs
Description: The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
Study: NCT03358706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Description: Participants will receive 20 mg capsule of omeprazole as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Description: Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan 30 mg
Description: Participants will receive 30 mg capsule of dextromethorphan as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Description: Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Description: Participants will receive 100 mg tablet of caffeine as a component of the Cytochrome P 450 probe cocktail orally.
Study: NCT03478683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to match tiotropium
Description: Subjects will receive tiotropium matching placebo via Handihaler once daily in the morning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELLIPTA
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Subjects will receive FF/UMEC/VI 100/62.5/25 mcg and matching placebo via ELLIPTA in the treatment period. Budesonide/formoterol plus tiotropium once daily plus placebo will be administered via ELLIPTA during the run-in period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MDI
Description: Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Subjects will receive budesonide/formoterol and placebo to match budesonide/formoterol via MDI in the treatment period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HandiHaler
Description: Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HandiHaler
Description: Subjects will be administered tiotropium (18 mcg) or placebo to match tiotropium via HandiHaler during the treatment period.